Interviews

Christopher Twelves, MD, Professor of Clinical Cancer Pharmacology and Oncology, University of Leeds, discusses a pooled analysis of eribulin for the treatment of patients with breast cancer.

Thomas J. Lynch, MD, discusses challenges associated with treating patients with lung cancer with molecular targeted therapies.

Bayard L. Powell, MD, discusses a phase I study that looked at CPI-613 in combination with high dose ARA-C and mitoxantrone for the treatment of patents with relapsed/refractory acute myeloid leukemia (AML).

Jason D. Wright, MD, discusses progression-free survival (PFS) as an endpoint for ovarian cancer trials.

Adam Bass, MD, assistant professor, Harvard Medical School, Dana-Farber Cancer Institute, provides an overview of the four subtypes of gastric cancer identified in a recent study.

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the utility of cabazitaxel for prostate cancer.

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center at the University of Pennsylvania, discusses next-generation sequencing in thyroid cancer.

Randall F. Holcombe, MD, professor, Chief Medical Officer, Cancer, Mount Sinai Health System, discusses the benefits and challenges associated with stool DNA test for colon cancer.

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the evolving role of chemotherapy for hormone-sensitive prostate cancer.

Susan Galbraith, MD, PhD, provides an overview of the ongoing phase I/II AURA study.

Brittany N. Bohinc, MD, Division of Endocrinology, Duke University, discusses the potential to use LGR5 as a biomarker in papillary thyroid cancer.

Paul A. Bunn, Jr., MD, professor of medicine in medical oncology, head of the division of medical oncology, University of Colorado, discusses stopping treatment with a TKI before starting chemotherapy.

Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses future treatment options for triple-negative breast cancer (TNBC).

Ruth M. O’Regan, MD, director, Translational Breast Cancer Research, professor, hematology and oncology, medical oncology, Winship Cancer Institute, Emory University, discusses the mechanism of action of trastuzumab.

Heather Wakelee, MD, associate professor, Stanford University School of Medicine, discusses the need to combine agents for the treatment of lung cancer.

Daniel P. Petrylak, MD, discusses the results of the phase II STRIDE study in metastatic castration-resistant prostate cancer (mCRPC).

Julie R. Gralow, MD, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Care Center, University of Washington School of Medicine, discusses future research into bisphosphonates in breast cancer.

Robert J. Motzer, MD, attending physician, Memorial Sloan Kettering Cancer Center, discusses nivolumab for the treatment of metastatic renal cell carcinoma.

David S. Klimstra, MD, discusses the impact of tumor heterogeneity during disease progression. This was the topic of a talk given by Oliver G. McDonald, MD, PhD, at the 2014 NANETS Symposium.

Jacques Raphael, MD, clinical fellow, Sunnybrook Odette Cancer Centre, discusses a study looking at the impact of Angelina Jolie’s decision and announcement to undergo a preventive double mastectomy.

Quincy Chu, MD, associate professor, medical oncologist, University of Alberta, discusses the development of ceritinib.

Sameek Roychowdhury, MD, PhD, from OSUCCC – James, discusses the benefit of a precision cancer medicine clinic.

Siavash Jabbari, MD, discusses the potential for implantable cardiac devices such as pacemakers to malfunction following radiation therapy.

Melanie B. Thomas, MD, discusses the rationale of a phase II study of adjuvant capecitabine/gemcitabine for extrahepatic cholangiocarcinoma and gallbladder carcinoma.

Edwin M. Posadas, MD, FACP, discusses the results of a phase Ib study that looked at abiraterone and docetaxel for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

William D. Tap, MD, discusses the potential to combine KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas.

Paul A. Bunn, Jr., MD, Giant of Cancer Care: Lung Cancer, professor of medicine in medical oncology, head of the division of medical oncology, University of Colorado, discusses the potential benefit for a blood-based test to detect a T790M mutation in lung cancer.

Michael Sawyer, MD, associate professor, Medical Oncology, University of Alberta, discusses lean body mass as a clinical outcome in multicentric Castleman’s disease.

Andrew R. Allen, BM, BCh, MA, MRCP, PhD, Executive Vice President of Clinical and Pre-Clinical Development, Chief Medical Officer, Co-Founder, Clovis Oncology, discusses how patients are selected for treatment with CO-1686.

Igor Puzanov, MD, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the rationale behind a phase Ib study to evaluate the efficacy and safety of T-VEC and ipilimumab in previously untreated, unresected stage IIIB-IV melanoma